Patent Application
20230173025
The present invention relates to Fetuin A (AHSG) for use in a method for treating a renal disorder, wherein an amount of Fetuin A effective for treating the renal disorder is administered to a subject in need thereof, in particular wherein the renal disorder is an ischemic disorder. The present invention also relates to a pharmaceutical composition for use in treating a renal disorder, comprising Fetuin A and optionally at least one pharmaceutical acceptable carrier.
An aim of modern medicine is to provide new treatments, including new targets in order to achieve better outcomes for particular patient groups. Those treatments, which take into account a patient’s needs or risks, can rely on findings, targeting for example pathological signalling cascades in the cell or malfunction of cellular responses. Medicinal protein chemistry is a broad field, where physical, chemical, biological, bioinformatics and medical techniques are used to analyse and describe protein structures and mechanisms, identify fundamental molecular and genetic errors of disease and to develop interventions to correct them. This perspective emphasizes cellular and/or molecular phenomena and involvements rather than the former conceptual and observational focus on patients and their organs. Treatments with proteins require appropriate proteins and treatment recommendations, in order to identify those patients who benefit from certain therapeutic measures. Therefore, the development of treatments critically depends on the investigation of new molecular targeting drugs and procedures.
Ischemia reperfusion injury (IRI) is often involved in a wide range of pathologies, including ischemic stroke, myocardial infarction, acute kidney injury, cardiovascular surgery and organ transplantation. When the blood supply returns to the tissue after ischemia, this reoxygenation causes tissue damage. Paradoxically the as such necessary reoxygenation, exacerbates cellular dysfunction and apoptosis, following restoration of blood flow to formerly ischemic tissues. IRI occurs in a wide range of organs including the heart, lung, kidney, gut, skeletal muscle and brain and may involve not only the ischemic organ itself but may also induce systemic damage to distant organs, potentially leading to multi-system organ failure. Reperfusion injury is a multi-factorial process resulting in extensive tissue destruction. Initially, lack of sufficient blood flow results in deficiencies in oxygen supply, glucose and other substances required for normal mitochondrial metabolism, including reduced levels of ATP.
This lack of ATP production causes cellular ATP-dependent ionic pumps (including the Na+/K+ and Ca2+ pumps) to fail and the transmembrane ionic gradients get lost. Damaged or dying cells suffer calcium overload, which is characterized by calcium accumulation in mitochondria or apoptotic bodies, respectively. Concomitant low levels of ATP (malfunctioning mitochondria) and pyrophosphate levels (an important inhibitor of calcification) increases the calcification propensity of these organelles. A known complication in organ transplantation, which may also result from IRI, is delayed graft function (DGF). DGF describes a phenomenon where recipients that have undergone transplantation have a poor graft function during the first weeks after transplantation and need dialysis.
Therapeutic modalities to render organs more resistant to damages caused by ischemia and reperfusion have given controversial results or are just emerging. Therapeutic options to either enhance the resistance of organs against IRI or to rescue organs after sudden oxygen restriction, have been the subject of major research efforts in the past decades. Such strategies are, for example ischemic preconditioning, an experimental strategy in which exposure to short, non-lethal episodes of ischemia result in attenuated tissue injury during subsequent IRI, metabolic strategies to increase ischemia tolerance (glycolytic enzymes, erythropoeitin, etc. under the control of the transcription factor HIF-1α), therapeutic gases, such as hydrogen, nitric oxide, hydrogen sulfide and carbon monoxide and also microRNAs (miRNAs) as therapeutic targets. Unfortunately, these modalities have given controversial results or are just emerging. Thus, treatment of renal disorders including, but not limited to IRI, remains an important unmet need.
Accordingly, there is a need for providing agents for treating renal disorders and the present invention offers a straightforward approach to address renal disorders, including ischemia reperfusion injury, in various settings.
Naturally occurring Fetuin A, also known as alpha-2-HS-glycoprotein (AHSG), is a liver-derived plasma glycoprotein, which is encoded by the AHSG gene. Fetuin A has been described in the art to attenuate early cerebral ischemic injury in a cerebral context, where IRI-driven inflammation has been diminished in rats with ischemic brain tissue (see, for example, Wang et. al, J Cereb Blood Flow Metab. 2010; 30(3): 493-504.). Fetuin A has further been related to the prevention of brain damage in stroke (WO 00/60943). However, it was also found that elevated plasma levels of Fetuin A increase the risk for myocardial infarction and ischemic stroke, showing that the role of Fetuin A as a prophylactic agent is not fully understood for ischemic brain damage (Weickert et. al, Circulation. 2008; 118: 2555-2562).
Contradictory data has also been presented with regard to the use of Fetuin A as a biomarker for renal disorders. For example, recent studies, investigating the role of Fetuin A as biomarker in kidney transplantation, have failed to provide predictive information about the clinical outcome of patients (see, for example, Roos et. al, Kidney Blood Press Res. 2011; 34(5): 328-33; Mersai et. al, Urol J. 2015; 12(3): 2182-6; Koca et. al, Nephrology Dialysis Transplantation. 2017, 32(3): iii419-iii420). In said publications, Fetuin A levels generally were measured in the peripheral blood, which does not reflect Fetuin A levels in tissue. Taken together, these publications suggest that Fetuin A levels in blood are not a useful biomarker for long-term survival or clinical prognosis of patients, which suffer from renal disorders.
However, in the context of the present invention, it was surprisingly found that the administration of Fetuin A attenuates kidney tissue damage induced by hypoxic conditions in kidneys.
Therefore, in a first aspect, the present invention relates to a Fetuin A (AHSG) for use in a method for treating a renal disorder, wherein an amount of Fetuin A effective for treating the renal disorder is administered to a subject in need thereof. Preferably, the renal disorder results from hypoxia, e.g. hypoxia during transplantation, cardiovascular surgery or other major surgery. The renal disorder may be an ischemic renal disorder.
Without being bound by any theory and based on the experimental evidence provided herein, it is believed that when Fetuin A is administered to a subject in need thereof, in particular to a subject suffering from an ischemic renal disorder, it acts as “mineral scavenger” in hypoxic renal tissues by “clearing” calcium-levels. Fetuin A is believed to counteract ectopic calcification to maintain renal tissue integrity and preventing inflammatory downstream cascades that may lead to renal fibrosis by IRI-induced expression of collagens. The herein proposed explanation is that Fetuin A, acts as a “mineral chaperone” in renal disorders, protects organs against ischemia reperfusion injury in kidney by clearing calcium-containing particles and mitigates the deleterious inflammatory response.
As used herein “renal disorder” is defined as one or more disorders or diseases affecting the kidney. The term encompasses renal diseases, but is not limited to them. For example, a renal injury that is not caused by a disease may also be a renal disorder (e.g. some injuries caused during major surgery; although major surgery may also be the cause a kidney diseases). Preferably, the renal disorder is an ischemic renal disorder, i.e. a renal disorder resulting from and/or associated with ischemia. When a renal disorder “is” a certain disorder, this does not preclude the presence of other disorders and multiple other disorders may occur independently or interdependently at the same time as said renal disorder, e.g. IRI and DGF may occur simultaneously.
In a preferred embodiment of the invention, the renal disorder is selected from the group consisting of acute renal disorders, chronic renal disorders, kidney fibrosis, chronic kidney disease (CKD), renal insufficiency, renal inflammation, acute kidney injuries (AKI), ischemic renal disorders, disorders related to kidney hypoxia, renal ischemia-reperfusion injury (IRI), kidney tissue damage, disorders related to kidney transplantation, disorders related to cardiovascular surgery and combinations thereof, in particular wherein the kidney tissue damage is ischemic kidney tissue damage. A disorder related to cardiovascular surgery may for example be kidney tissue damage caused by cardiovascular surgery, in particular caused by hypoxia and/or ischemia during cardiovascular surgery.
In another embodiment of the invention, the ischemic renal disorder is selected from the group consisting of ischemic acute renal disorders, ischemic chronic renal disorders, kidney fibrosis resulting from ischemia, renal inflammation resulting from ischemia, acute kidney injuries resulting from ischemia, ischemic renal disorders, disorders related to kidney hypoxia, renal ischemia-reperfusion injury, ischemic kidney tissue damage, disorders related to ischemia during kidney transplantation (e.g. delayed graft function) and combinations thereof.
“Acute renal disorders” as used herein relate to a sudden functional loss or reduction of kidney function. This can be triggered by acute accidental kidney damage or acute occurring disorders. The causes for this are numerous, including, but not limited to pre-renal, post-renal and intrinsic acute kidney failure. Acute kidney failure can also be triggered by systemic diseases (such as a manifestation of an autoimmune disease), crush injury, contrast agents, some antibiotics and more.
“Chronic renal disorders” such as chronic kidney disease (CKD), chronic renal insufficiency or chronic renal inflammation, such as chronic pyelonephritis, are also included to a possible treatment spectrum, but not limited to those. “Chronic renal disorders” can either be triggered by anatomical location including, but not limited to those, vascular disease including large vessel disease such as bilateral kidney artery stenosis and small vessel disease such as ischemic nephropathy, hemolytic-uremic syndrome and vasculitis, glomerular disease, tubulointerstitial disease, obstructive nephropathy or congenital disease such as polycystic kidney disease or mesoamerican nephropathy.
“Fibrosis” relates to the formation of excess fibrous connective tissue, for example in a kidney or kidney tissue. Tissue inflammation may trigger fibrosis. In some embodiments, the fibrosis relates to interstitial fibrosis.
“Ischemia” or “ischemic” as used herein is an inadequate blood supply to an organ or specific part of the body. It is generally considered a severe clinical problem. Ischemia leads to a reduction in the supply of blood, hence results in a reduction of supply with oxygen and nutrients and also involves a reduced removal of waste products from tissues. This can result in irreversible tissue damage and cell death. Ischemia may occur in the context of and may be the cause of multiple renal disorders. Ischemia may also occur in the context of major surgery, e.g. it may be caused by major surgery. “Reperfusion” is herein defined as restoration of blood supply after an ischemic event. It may cause tissue damages by imbalancing, among others, the mineral balance, in particular by accumulation of calcium, e.g. in a kidney. “Ischemic reperfusion injury” (IRI), sometimes called reperfusion injury (RI) or re-oxygenation injury, is the tissue damage caused when blood supply returns to tissue (reperfusion) after a period of ischemia and/or after a period of reduced oxygen supply (hypoxia).
“Cardiovascular surgery” as used herein relates to the surgical treatment of great vessels and organs inside the thorax or abdomen, e.g. surgery involving heart, great vessels or lung. In some embodiments, cardiovascular surgery may be coronary artery bypass surgery or abdominal aortic aneurysm surgery. Abdominal aortic aneurysm surgery may cause renal ischemic reperfusion injury. Even if a cardiovascular surgery is not directly performed on the kidney, renal disorders may be associated with it. Ischemia during cardiovascular surgery may occur and cause kidney tissue damage. The development of acute kidney injury (AKI) after cardiovascular surgery is well known and some embodiments relate to the treatment of acute kidney injury resulting from cardiovascular surgery.
In context of the present invention, a “subject in need thereof” generally refers to either a human being, who is expected to suffer or is at risk to suffer from a renal disorder or a human being who already suffers from the renal disorder, in particular has already been diagnosed with a renal disorder, preferably an ischemic renal disorder. The subject may also be referred to as “patient”. The subject may be in need of prophylactic or therapeutic treatment. The expectation to have an increased risk to suffer from a renal disorder may in some embodiments be due to a scheduled major surgery during which the occurrence of ischemia is a risk or even expected, e.g. an increased risk of a renal disorder in view of a scheduled kidney transplantation or cardiovascular surgery. In some embodiments, the subject in need thereof is expected to undergo or has undergone major surgery, preferably is expected to undergo or has undergone kidney transplantation or cardiovascular surgery.
“Treatment”, “treat” or “treating” as used herein encompasses therapeutic treatment as well as prophylactic treatment (prevention) of a disorder. “Treatment”, “treat” or “treating” may include administering a protein or compound described herein to thereby (i) reduce or eliminate at least one symptom of a specified disorder or (ii) to slow progression of the disorder or (iii) to stop or hinder the development of at least one symptom of a specified disorder. “Therapeutic treatment” and “therapeutic treating” as used herein refer to the treatment of an existing disorder, i.e. a treatment after the commencement of said disorder and its purpose is to eliminate, alleviate or slow down the existing disorder or to reduce the severity of it. In contrast, “prophylactic treatment”, “prevention”, “prevent” or “preventing” as used herein refer to a type of treatment for the disorder intended to reduce the risk, prevent or delay that a subject who does not presently have said disorder will develop it or symptoms and/or signs of it in the future, in particular after an event like a major surgery such as a transplantation. In a preferred embodiment, therapeutic treatment means improving the prognosis of the disorder. In some embodiments, prophylactic treatment is done before, during and/or after a major surgery such as a kidney transplantation or cardiovascular surgery to reduce the risk of onset for a disorder associated with major surgery, in particular associated with ischemia during kidney transplantation or cardiovascular surgery. In some further embodiments, the term “treating” or “treatment” preferably means that not only symptoms of the disorder are relieved but also that the disorder itself is improved, delayed or prevented, in particular that the disorder has a reduced severity or is prevented. Furthermore, “treatment” and “treating” may comprise the administration or the application of a therapeutic agent to a subject or patient or performance of a procedure or modality on a subject for obtaining a therapeutic or prophylactic benefit in relation to a disorder. For example, a treatment may include administration of a pharmaceutically effective amount of Fetuin A. In some embodiments, the above-mentioned disorder is a renal disease.
In an embodiment, the invention relates to Fetuin A for use in a method for treating a renal disorder, in particular therapeutically treating a renal disorder, wherein an amount of Fetuin A effective for treating the renal disorder is administered to a subject suffering from the renal disorder. In some embodiments, the renal disorder is an ischemic renal disorder. In this context, “treatment” or “treating” means the treatment of an established renal disorder and/or the treatment after the onset of said renal disorder.
In an alternative embodiment, the invention relates to Fetuin A for use in a method for prevention, also called prophylactic treatment, of a renal disorder, wherein an amount of Fetuin A effective for preventing the renal disorder is administered to a subject in need thereof, in particular to a subject who is at risk of suffering from the disorder in the future, e.g. a subject who is scheduled for major surgery that may involve ischemia of the kidney. In said alternative embodiment, “treatment” or “treating” mean “prevention” or “preventing” of a renal disorder before the onset of said disorder. In some cases at least one dose of Fetuin A is administered within 48 hours before a surgery, in particular transplantation surgery, comprising ischemia.
In another embodiment of the present invention, the renal disorder is a disorder related to, in particular caused by, kidney transplantation, in particular wherein said disorder is selected from the group consisting of delayed graft function (DGF) organ rejection of kidney transplants, kidney tissue damage resulting from kidney transplantation, inflammation resulting from kidney transplantation, ischemia reperfusion injury (IRI) resulting from kidney transplantation and combinations thereof. In some embodiments of the present invention, the renal disorder is a disorder caused by kidney transplantation, wherein said disorder is selected from the group consisting of delayed graft function, kidney tissue damage resulting from kidney transplantation, ischemia reperfusion injury resulting from kidney transplantation and combinations thereof.
In some embodiments, the renal disorder is an ischemic renal disorder, in particular an ischemic renal disorder resulting from kidney transplantation or cardiovascular surgery.
In another preferred embodiment of the present invention, the renal disorder, in particular the ischemic renal disorder, is related to or caused by hypoxia, in particular wherein the hypoxia is caused by ischemia during major surgery, for example ischemia during cardiovascular surgery or kidney transplantation.
“Major surgery” as used herein is defined by an invasive operative procedure, in particular an invasive operative procedure in which a resection is performed. Major surgery may comprise that a body cavity is entered, organs are removed, organs are transplanted and/or normal anatomy is altered. In some embodiments, major surgery comprises local or general anaesthetization of the subject. In general, if a mesenchymal barrier is opened (pleural cavity, peritoneum, meninges), the surgery is considered “major”. For example, kidney transplantation and cardiovascular surgery both are major surgeries. When the term “surgery” is used without specifying that it is a major surgery, this also comprises embodiments of “major surgery” in accordance with this invention.
In the context of the present invention, “kidney tissue damage” includes all forms of tissue damage, such as caused accidentally, caused by all cases of hypoxia, in particular hypoxia during kidney transplantation, cardiovascular surgery or other major surgery.
“Hypoxia” as used herein refers to a condition in which the body or a region of the body is deprived of adequate oxygen supply at the tissue level. It is often part of a pathological disorder. Hypoxia induced tissue damage includes all disorders, where oxygen supply is lost or diminished, causing oxygen undersupply in any tissue. This also includes reduced blood supply due to major surgery or blood vessel damages in general. The term “hypoxia” also includes anoxia as an extreme form of hypoxia, i.e. the total depletion in the level of oxygen.
In another preferred embodiment of the present invention, the IRI is caused by hypoxia during surgery, in particular major surgery. Hypoxic disorders, occurring in course of such a surgery, in particular a major surgery, can lead to ischemic reperfusion injury in the kidney, thereby damaging the tissue. The ischemic reperfusion injury at least partially may be caused by calcification.
In a further embodiment of the present invention, the renal disorder is delayed graft function, renal fibrosis or a combination thereof.
“Fetuin A” as used herein refers to a protein or fragment thereof or derivative thereof which either is naturally occurring Fetuin A or is not naturally occurring, but has the same or similar function as naturally occurring Fetuin A, in particular the same or similar function as naturally occurring human Fetuin A. Preferably, it is an inhibitor of calcification and/or the protein sequence is at least partially identical to human Fetuin A. In some embodiments, Fetuin A is a plasma derived or recombinant human Fetuin A. Human plasma derived Fetuin A is obtained from human plasma. The term Fetuin A shall also encompass all natural occurring alleles, splice variants and isoforms as well as synthetic peptides, peptide mimetics or peptide fragments, which have the same or similar functions as naturally occurring and/or human Fetuin A, such as inhibition of calcification.
In some embodiments of the present invention, the Fetuin A is human Fetuin A. In some embodiments, the human Fetuin A is derived from human blood plasma or, alternatively, the human Fetuin A is recombinant human Fetuin A. Plasma-derived human Fetuin A may be purified from human plasma. Recombinant human Fetuin A may have a different glycosylation pattern than plasma-derived human Fetuin A. In some embodiments Fetuin A is naturally occurring Fetuin A. A “naturally occurring protein” as referred to in the context of the present invention generally denotes a protein which is naturally found in any kind of living organism and which can as such be isolated from tissues, liquids, and/or from any sort of individual cells of said organism. For example, some naturally occurring proteins can be obtained from blood plasma of humans. Recombinantly produced proteins also include Fetuin A derivatives, which are somehow marked or labelled, for example by attaching gene-tags (such as FLAG-tag, His-tag, Myc-tag, HA-tag or fluorescently labelled proteins such as GFP, YFP or RFP) that might or might not ease the purification.
“Purified” herein describes protein purification in general, which is well known to the skilled person in the art. In general, proteins can be purified based on their characteristics such as solubility, size, charge and specific binding affinity. That is, proteins are often separated based on their net charge by ion-exchange chromatography. Protein purification techniques are well known to the skilled person in the art. These techniques include, at one level, the homogenization and fractionation of the cells, tissue or organ to polypeptide and non-polypeptide fractions. The protein or polypeptide of interest may be further purified using chromatographic and electrophoretic techniques to achieve partial or complete purification (or purification to homogeneity) unless otherwise specified. Methods particularly suited to the preparation of a pure peptide are ion-exchange chromatography, gel exclusion chromatography, polyacrylamide gel electrophoresis, affinity chromatography, hydrophobic interaction chromatography, immunoaffinity chromatography and isoelectric focusing. A method of purifying peptides is high-performance liquid chromatography. Another protein purification method is the fast protein liquid chromatography. For example, purification of plasma proteins can be performed by blood plasma fractionation and/or chromatographic steps. Protein purification may also include virus inactivation as a step. The term “purified” does not preclude the presence of some impurities, but in general, other blood components and/or impurities have been largely removed.
In another preferred embodiment of the invention the functionally active derivative or fragment of human Fetuin A is at least 70%, preferably at least 80%, more preferably at least 90%, even more preferably at least 95% or most preferably at least 99% identical and/or homologous to SEQ ID NO: 1, as defined below. “Homologue” is herein defined as sequence similarity within different biological sequences, on RNA, DNA and protein sequence levels. A “functionally active derivative”, has the same or similar activity as naturally occurring Fetuin A, in particular may inhibit calcification. The percentage of sequence identity can be determined e.g. by sequence alignment. Methods of alignment of sequences for comparison are well known in the art. The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., 1990, J. Mol. Biol; 215:3, 403-410) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, MD) and the Internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx.
Hence, in another embodiment of the present invention the Fetuin A comprises or consists of an amino acid sequence according to SEQ ID NO: 1 or a fragment or fragments thereof. In the context of the present invention, the term “a fragment thereof” or “fragments thereof” refer to any amino acid sequence or peptide defined by SEQ ID NO: 1, including, but not limited to, every smaller fragment revealing activity of Fetuin A or any fragment comprising additional amino acids, as defined above for the fragments and derivates of naturally occurring proteins with Fetuin A activity. In some embodiments the length of said fragment is at least 20%, at least 30%, at least 40%, at least 50% at least 60%, at least 70%, at least 80% or at least 90% of the length of SEQ ID NO: 1, wherein the length relates to the number of amino acids with respect to the full-length of SEQ ID NO: 1. Fragments may comprise additional amino acids that are not part of SEQ ID NO: 1. Fragments of the protein of the present invention can be obtained by sequence alterations in the protein (e.g. by one or more amino acid deletions, substitutions and/or additions), wherein the protein with the sequence alterations retains a function of the unaltered protein, namely its ability to localize during cell cycle progression to subcellular structures selected from the group consisting of the cell cortex, the contractile ring and the midbody or to function as a fluorescence reporter protein. Such sequence alterations can include, but are not limited to, conservative substitutions, deletions, mutations and/or insertions.
Human Fetuin A sequences (protein and nucleic acid sequences) are available from the “National Center for Biotechnology Information” (NCBI):
SEQ ID NO.: 1 (protein sequence of human Fetuin A)
Protein Sequence: NP_001341500.1 (368 amino acids) (https://www.ncbi.nlm.nih.gov/protein/NP_001341500.1)
SEQ ID NO.: 2 (nucleic acid sequence of human Fetuin A)
Nucleotide Sequence: NM_001354571.2 (1107 nucleotides) (https://www.ncbi.nlm.nih.gov/gene/197; NM_001354571.2 ; Consensus Coding Sequence CCDS87176.1).
In another preferred embodiment, the functionally active derivative or fragment of the naturally occurring protein Fetuin A is at least 70%, preferably at least 80%, more preferably at least 90%, even more preferably at least 95% or most preferably at least 99% identical and/or homologous to SEQ ID NO: 3 (bovine Fetuin A sequence), as defined below.
SEQ ID NO.: 3 (protein sequence of bovine Fetuin A)
Protein Sequence: NP_776409.1 (359 amino acids) (https://www.ncbi.nlm.nih.gov/protein/NP_776409.1)
SEQ ID NO.: 4 (nucleic acid sequence of bovine Fetuin A)
Nucleotide Sequence: NM_173984.3 (Coding Nucleotide Sequence (1080 nt). (https://www.ncbi.nlm.nih.gov/nuccore/NM_173984.3)
In another embodiment of the present invention, the Fetuin A is recombinantly expressed, preferably in a host cell system providing posttranslational modifications, more preferably glycosylations.
The term “expressed” as used herein generally means allowing or causing the information in a gene or a DNA sequence to become manifest. In particular, in the context of the present invention, it means the intracellular production of the protein encoded by the nucleic acid expression construct of the present invention by activating the cellular functions involved in transcription and translation of the corresponding gene or DNA sequence. That is, a DNA sequence is expressed in or by a cell to form an “expression product” such as a protein. The expression of a protein in or by a cell may depend on a variety of factors, including, but not limited to, the promoter sequence which is operably linked to the DNA sequence encoding the protein of interest, the presence or absence of enhancer and/or silencer sequences or other DNA sequences which control the rate of transcription, the cell culture conditions applied to the cell carrying the respective DNA sequence including the media used for culturing the cell, and/or the number of copies of DNA sequences introduced into the cell. Successful expression of the fusion protein may be analyzed and/or visualized by standard methods known to the person skilled in the art, including, but not limited to, Western Blot analysis, Northern Blot analysis, RNase protection assays, quantitative RT-PCR, as well as methods concerning direct or indirect fluorescence readout. “Recombinant” and “recombinantly” means artificially produced, relating to or denoting an organism, cell, protein or genetic material formed by recombination. Recombinant expression of desired protein is a standard method in the art, which is followed by standard protein purification methods as described below.
“Post-translational modifications” increase the functional diversity of the proteome by the covalent addition of functional groups or proteins, proteolytic cleavage of regulatory subunits or degradation of entire proteins. These modifications include, among others, phosphorylation, ubiquitination, S-nitrosylation, methylation, N-acetylation, lipidation and glycosylation.
A “host cell providing post-translational modifications” is a host cell, which delivers necessary modification modalities, enabling correct post-translational modification of mammalian proteins. Systems, which provide these requirements are for example insect cell expression systems, such as BTI-Tn5B1-4 or SF9 cell lines or mammalian cell expression systems, such as for example, but not restricted to those HEK 293 (T), CHO or HELA cells.
“Glycosylation” is defined as an enzyme-directed site-specific process that links saccharides to produce glycans, which in turn are attached to proteins, lipids or other organic molecules. Protein glycosylation as post-translational process is a natural process in cells by which saccharides are selectively added to specific protein residues in order to convey more structural stability or function to the native protein structure. Thereby, Glycosylation plays an important role in the proper functionality of a huge variety of proteins. Glycosylation includes, but is not limited to C-linked, N-linked, O-linked or S-linked glycosylation and glycation. “Glycation” thereby refers to the non-enzymatic attachment of reducing sugars to the nitrogen atoms of proteins.
An “injection” as used herein is a parenteral mode of administration, which does not encompass oral administration or inhalation. As used herein “injection” encompasses intravenous (iv), intraarterial, intramuscular (im), subcutaneous (sc) and intradermal (id), intraperitoneal, intraosseous, intracardiac, intraarticular and intracavernous administration. In some advantageous embodiments, injection refers to intravenous (iv) or subcutaneous (sc) administration. The injection may be a discontinuous and/or short-time injection, for example using a needle with a single dose of Fetuin A (and optionally injecting further doses at a later time). Alternatively, the injection may also be an infusion, i.e. a continuous injection for a longer time. In some embodiments an injection is administered within less than 15 min, in particular within less than 10 or within less than 5 min. Administration by injection also includes systemic administrations, for example administration via extracorporeal circulation (ECC). “Inhalation” as used herein describes the process of inhaling or breathing in, which may transport air, gases, active substances and aerosols into the lungs. For example, Fetuin A may be provided as part of an aerosol for the purpose of inhalation.
In some embodiments of the present invention, the Fetuin A is administered to the patient by way of injection or inhalation. In some preferred embodiments, Fetuin A is administered to the patient by way of injection. In some embodiments, Fetuin A is administered to the patient by way of intravenous (iv), intramuscular (im) or subcutaneous (sc) injection, preferably intravenous (iv) injection.
In some embodiments, the Fetuin A is administered to the patient in an amount effective for treating the renal disorder, in particular wherein the Fetuin A is administered to a patient in a concentration range from 1 mg/kg to 200 mg/kg of body weight, in particular administered intravenously. In some embodiments, Fetuin A is administered to a patient in a concentration range from 5 mg/kg to about 100 mg/kg of body weight, in particular administered intravenously. In some embodiments, Fetuin A is administered to a patient in a concentration range from 10 mg/kg to about 50 mg/kg of body weight, in particular administered intravenously. In some embodiments, Fetuin A is administered to a patient in a concentration range from 10 mg/kg to about 75 mg/kg of body weight, in particular administered intravenously. In some embodiments, Fetuin A is administered to a patient in a concentration range from 20 or 30 mg/kg to about 200 mg/kg of body weight, in particular administered intravenously. In some embodiments, Fetuin A is administered to a patient in a concentration range from 20 mg/kg to about 50 mg/kg of body weight, in particular administered intravenously. In some embodiments, Fetuin A is administered to a patient in a concentration range from 30 mg/kg to about 50 mg/kg of body weight, in particular administered intravenously.
In a further embodiment, the Fetuin A is administered to the subject in need thereof during major surgery, for example during cardiovascular surgery or during kidney transplantation. In a further embodiment, the Fetuin A is administered to the subject in need thereof after major surgery, for example after cardiovascular surgery or after kidney transplantation. In a further embodiment, the Fetuin A is administered to the subject in need thereof before major surgery, for example before cardiovascular surgery or before kidney transplantation. These embodiments may be combined, e.g. in some embodiments Fetuin A is administered before and after major surgery.
In the context of the present invention Fetuin A may be a target of the transcription factor HIF-1α. HIF-1α, also known as Hypoxia-inducible factor 1-alpha, is a subunit of a heterodimeric transcription factor hypoxia-inducible factor 1 (HIF-1). “Target” is herein defined as a protein, which is affected “downstream”, relating to a cellular signaling pathway or cascade. In the context of the present invention, Fetuin A may act downstream of HIF-1α.
In some embodiments of the present invention, the treatment comprises modulation of calcification levels in the kidney tissue, preferably hypoxia-related calcification levels. “Calcification” is hereby defined as the accumulation of calcium salts in a body tissue, in particular in the kidney that might lead to permanent damage of the tissue. It may lead to inflammatory response and tissue damage as a consequence of restricted oxygen supply in the tissue. In an embodiment, the treatment comprises removal of calcium mineral depositions in kidney tissue, in particular the removal of calcium mineral depositions in transplanted kidney tissue.
In another embodiment of the invention, at least two doses of the Fetuin A are administered or at least three doses of the Fetuin A are administered. In some embodiments, at least four doses of the Fetuin A are administered. In another embodiment of the invention the treatment of the subject comprises a treatment phase with at least daily or weekly administration of at least one dose of Fetuin A, preferably in the week or month after an ischemic incident and/or after surgery, in particular after major surgery.
In the context of the present invention the term “ischemic incident” refers to any event that causes and/or comprises ischemia, in particular that comprises ischemia. A surgery may be an ischemic incident when blood supply to tissue is restricted during said surgery. For example, during a kidney transplantation procedure the graft often cannot adequately be perfused with blood. A sudden blood loss during an accident can also be an ischemic incident during which the kidney is not adequately perfused. In some embodiments, the ischemic incident is ischemia in major surgery, in particular wherein the major surgery is kidney transplantation or cardiovascular surgery.
In another embodiment of the invention at least one dose of Fetuin A is administered prior, during or after an ischemic incident and/or surgery, in particular major surgery. In some embodiments the ischemic incident and/or the surgery is kidney transplantation or cardiovascular surgery.
In yet another embodiment of the invention, at least one dose of Fetuin A is administered within 48 hours, in particular within 24 hours, before or after an ischemic incident, such as kidney transplantation or cardiovascular surgery. In some embodiments, the at least one dose of Fetuin A is administered within 48 hours, in particular within 24 hours, after the ischemic incident. In yet another embodiment, at least one dose of Fetuin A is administered within 48 hours, in particular within 24 hours, before a major surgery. In yet another embodiment, at least one dose of Fetuin A is administered within 48 hours, in particular within 24 hours, after a major surgery. In some further embodiments, Fetuin A is administered during major surgery. Said major surgery is kidney transplantation or cardiovascular surgery in some embodiments.
In yet another embodiment of the invention, at least one first dose of Fetuin A is administered within 48 hours, in particular within 24 hours, before an ischemic incident and at least one second dose of Fetuin A is administered within 48 hours, in particular within 24 hours, after the ischemic incident. In some embodiments, the at least two doses of Fetuin A are administered within 48 hours, in particular within 24 hours, before an ischemic incident. In yet another embodiment, at least two doses of Fetuin A are administered within 48 hours, in particular within 24 hours, before a major surgery. In yet another embodiment, two or three doses of Fetuin A are administered within 48 hours, in particular within 24 hours, before a major surgery. In some embodiments, the at least two doses of Fetuin A are administered within 48 hours, in particular within 24 hours, after an ischemic incident. In yet another embodiment, at least two doses of Fetuin A are administered within 48 hours, in particular within 24 hours, after a major surgery. In yet another embodiment, two or three doses of Fetuin A are administered within 48 hours, in particular within 24 hours, after a major surgery.
In some embodiments, the Fetuin A is administered to the patient for a treatment period at least once weekly, in particular at least once every 48 hours, preferably at least once every 24 hours.
In some embodiments, Fetuin A is administered in divided doses over a total duration of 1 to 100 days, in particular over a total duration of 1 to 50 days. In another embodiment, Fetuin A is administered in divided doses over a total duration of 1 to 25 days. In another embodiment, Fetuin A is administered in divided doses over a total duration of 1 to 10 days. In another embodiment, Fetuin A is administered in divided doses over a total duration of 2 to 10 days.
In an embodiment of the present invention, the treatment comprises administering Fetuin A as part of a pharmaceutical composition to the subject in need thereof. Preferably, the pharmaceutical composition is in liquid form. Preferably, said pharmaceutical composition is in accordance with one or more of the embodiments as defined below in the second aspect of the present invention.
In a second aspect, the present invention relates to a pharmaceutical composition for use in treating a renal disorder, comprising Fetuin A (AHSG) and optionally at least one pharmaceutical acceptable carrier. In some embodiments, the second aspect relates to the pharmaceutical composition for use in a method for treating a renal disorder, wherein an amount of Fetuin A effective for treating the renal disorder is administered to a subject, preferably a patient, in need thereof.
A “pharmaceutical carrier” as referred to herein may be any substrate used in the process of drug delivery, which serves to improve the selectivity, effectiveness, and/or safety of drug administration.
The pharmaceutical composition in accordance with the second aspect may be for used for the same treatments and renal disorders as described above in relation to Fetuin A and any treatments described above also may describe embodiments of the pharmaceutical composition for use in such treatments. In a preferred embodiment of this second aspect, the renal disorder is selected from the group consisting of acute renal disorders, chronic renal disorders, kidney fibrosis, chronic kidney disease, renal insufficiency, renal inflammation, acute kidney injuries, ischemic renal disorders, disorders related to hypoxia, renal ischemia-reperfusion injury, kidney tissue damage, preferably ischemic kidney tissue damage, disorders related to kidney transplantation, disorders related to cardiovascular surgery and combinations thereof.
In some embodiments, the pharmaceutical composition is a liquid. In some embodiments, the pharmaceutical composition comprises water.
In another embodiment of this second aspect, the disorders related to kidney transplantation are selected from the group consisting of delayed graft function, organ rejection of kidney transplants, kidney tissue damage resulting from kidney transplantation, inflammation resulting from kidney transplantation, renal IRI resulting from kidney transplantation and combinations thereof.
Preferably, the renal disorder is caused by hypoxia during surgery, in particular major surgery. For example, the hypoxia may be caused by ischemia during kidney transplantation or cardiovascular surgery.
In equally preferred embodiments, the Fetuin A of the pharmaceutical composition is defined as described in detail above. The pharmaceutical composition may comprise any of the above-described embodiments of Fetuin A.
In the context of the pharmaceutical composition of the present invention, Fetuin A is preferably human Fetuin A, more preferably Fetuin A, which is derived from human blood plasma.
In an alternative embodiment the Fetuin A of the pharmaceutical composition is recombinantly expressed, preferably in a host cell system providing posttranslational modifications, in particular glycosylation.
Equally preferred in this context is that the Fetuin A is at least 70%, at least 80%, at least 90%, at least 95% or at least 99% identical and/or homologous to SEQ ID NO: 1. Also preferred is that the Fetuin A comprises or consists of SEQ ID NO: 1 or fragments thereof.
In an embodiment, the pharmaceutical composition is administered to a subject as described in detail above. Preferably, the pharmaceutical composition is formulated for injection or inhalation.
The following Figures and Examples are intended to illustrate various embodiments of the present invention. As such, the specific modifications discussed therein are not to be understood as limitations of the scope of the invention. It will be apparent to the person skilled in the art that various equivalents, changes and modifications may be made without departing from the scope of the invention and it is thus to be understood that such equivalent embodiments are to be included herein.
Chronic fetal hypoxia induces IUGR in mice. To model chronic fetal hypoxia, timed-mated pregnant mice were exposed to 10% oxygen from E14.5 to E18.5 (
Hypoxic fetal kidneys adopt a hepatic gene expression pattern. Next, a whole genome expression in fetal hypoxic kidneys was examined using gene arrays. 62 induced and 28 repressed genes were identified and compared to both control groups (
Fetuin A is produced locally in the proximal tubulus under hypoxic conditions. Interestingly, the gene with the highest induction (Ahsg) was found in 7 of the 10 annotation groups. Ahsg belongs to the cystatin superfamily of cysteine protease inhibitors, encoding for the negative acute phase glycoprotein Fetuin A, whose main function concerns mineralized matrix metabolism. Despite its strong induction in hypoxic kidneys, no significant rise could be detected in fetal plasma Fetuin A levels (
Ahsg harbours putative HIF binding sites overlapping with enhancer regions. Having shown that Fetuin A is locally produced in hypoxic fetal kidneys, it was assessed whether the expression of Ahsg was directly activated by hypoxia. To check for potential HIF binding sites (hypoxia response elements - HRE) in the human AHSG locus, HlF-1α (HIF-1-alpha) and HIF-2α (HIF-2-alpha) ChlP-seq datasets were used derived from hypoxic MCF7 cells. A cluster of potential HREs near exon 4 of human AHSG that overlapped with H3K27Ac and H3K4Me1 (chromatin marks of active enhancer elements) and DNasel hypersensitivity was identified. Another putative HRE was located in intron 1. Screening Ahsg genes of 15 species for the presence of the consensus HIF binding sites (RCGTG) 10kb upand downstream of the ATG revealed a peak 1-5 kb downstream of the ATG with an average number of 2 HREs per 1 kb window. Notably, not only the annotated human ChlP-seq HIF sites localized within this peak, but also four potential mouse HREs. Alignment of the latter with enhancer marks revealed a close association with H3K27Ac, H3K4Me1 and DNasel hypersensitivity.
Hypoxia activates Fetuin A transcription in vitro. Five putative HREs of mouse Ahsg and their surrounding DNA, alongside with nonsense mutations of these sites, were cloned into luciferase reporter plasmids (
Fetuin A deficiency aggravates CKD progression in hypoxic IUGR kidneys. To investigate how the induction of Fetuin A in fetal hypoxic IUGR kidneys affects renal function in the long term, urinary protein levels were measured and the glomerular filtration rate (GFR) was determined in adult mice (
Fetuin A deficiency promotes accumulation of calcium mineral particles and macrophages in hypoxic IUGR kidneys. Adult Fetuin A KO mice are prone to soft tissue calcification, however overt calcification in the kidneys of hypoxic Ahsg KO mice as assessed by von-Kossa staining was not detected. To still test whether the expression of Fetuin A in fetal hypoxic kidneys affected mineralized matrix handling for the presence of calcium containing nanoparticles was probed by incubating freshly cut kidney sections of E18.5 embryos with ATTO 488 fluorescently labelled Fetuin A (488-FA). Due to the high affinity binding of Fetuin A to calcium phosphate, 488-FA staining is more sensitive to detect calcium containing matrix and cell remnants than the commonly used mineral staining protocols. Thus, positive 488-FA staining in the absence of von-Kossa or Alizarin-Red staining also highlights structures merely enriched with calcium, including amorphous calcium-phosphate aggregates that often precede overt calcifications. 488-FA staining revealed in normoxic wt kidneys intense labelling of the PT, a site of major calcium resorption and thus also of mineralized matrix handling (
Fetuin A attenuates the hypoxia-induced expression of fibrosis markers by antagonising TGF-β signaling. Kidneys of fetal hypoxic Ahsg KO mice generally exhibited higher expression levels of fibrotic markers vs. fetal hypoxic wt animals (
Fetuin A significantly reduces in vivo the expression of fibrosis markers in the kidney after ischemia reperfusion injury. Next, the therapeutic potential of Fetuin A supplementation on the treatment of kidney injury was experimentally explored. To that purpose, a well-established mouse model of unilateral ischemia-reperfusion injury was used. This IRI model, as indicated by its name, best mimicks ischemia-reperfusion lesions in the kidney following cardiovascular surgery, kidney transplant or removal of renal tumors. It is straightforward and reproducible. Ischemia was induced in the left kidney by clamping the renal vessels for 30 min, the right kidney served as a control. It was first shown by accumulation of calcium mineral particles and macrophages in hypoxic lUGR kidneys that ischemia-reperfusion indeed induces deposition of calcium mineral nanoparticles in the operated kidney but not in the contralateral control kidney (
Prophylactic administration of human Fetuin A in mice undergoing ischemia reperfusion injury (IRI) led to less tissue damage and reduced fibrotic remodeling. 900 µg Fetuin A were injected intravenously 24 h and again 3 h before unilateral IRI of the left kidney (20 min ischemia time). PBS was injected in control animals. Kidneys were collected 24 h post operation, the right kidney served as control. Expression levels of early damage markers Kim1 (
Presence of exogenous Fetuin A in the renal tissue of mice after intravenous (iv) administration. No human Fetuin A was detected in PBS-injected samples (
Time course of human Fetuin A in the serum of mice upon intravenous administration. After 1 day, the detected amount of human Fetuin A in the serum was reduced compared to 1 minute or 1 hour post injection (
Animals. Breeding, genotyping and all animal experiments were conducted according to the Swiss law for the welfare of animals and were approved by the local authorities (Canton of Bern BE96/11, BE105/14 and BE105/17). All mice, including Ahsgtm1Mbl mice and Clcn5tm1Gug mice were maintained on a C57BL/6 background and were housed in IVC cages with free access to chow and water and a 12 h day/night cycle.
Induction of hypoxia in pregnant mice. For timed matings, females in breeding were checked for vaginal plugs every morning and if present the time point was set to gestational day (E) 0.5. AhsgKO mice were obtained from heterozygous breeding pairs, also giving rise to heterozygous and wt littermates that were used as controls. Daily food consumption (weight difference of the food initially provided and the food remaining after 24 h) during pregnancy and the maternal weight gain from E0.5 to E18.5 was recorded. For induction of hypoxia, E13.5 pregnant mice were transferred into a hypoxic glove box (Coy Laboratory Products, Grass Lake, USA). The next day, the oxygen content was gradually lowered to 10% within 6-8 hours with intermittent pauses at 16% and 12.5% to acclimatize the animals to the increasing hypoxic conditions. An electric fan inside the chamber maintained adequate air circulation. The CO2 level was kept low by chelating excess CO2 in soda lime (Sigma, 72073) filled cartridges connected to the air circulation system. Excess humidity was absorbed by silica gel orange granulate (Sigma, 1.01969), changed every day. Mice in the caloric control group received food matching the average amount of food consumed by the mice of the hypoxia group. Pregnant hypoxic or control mice were euthanized on E18.5 and fetuses and placentas were collected, weighed and prepared for further analysis. Fetal kidneys were dissected in PBS using a Leica M80 stereoscope. For primary proximal tubular cells (pPTC) preparation, kidneys of 3-4 weeks normoxic mice were isolated. Assessment of renal functions (GFR and proteinuria) was performed in 9 weeks old fetal hypoxic or normoxic.
Induction of ischemia and administration for therapeutic treatment experiments. For experiments in
Induction of ischemia and administration for prophylactic treatment (prevention) experiments. For experiments in
Transcutaneous assessment of glomerular filtration. The glomerular filtration rate (GFR) was determined in conscious animals as described in Schreiber, A. et al. Transcutaneous measurement of renal function in conscious mice. Am J Physiol Renal Physiol 303, F783-788 (2012). Briefly, the plasma clearance of FITC-sinistrin (Fresenius-Kabi, Ll9830076) is measured across the skin using light-emitting diodes with an emission maximum for FITC at 470 nm and a photodiode detecting the fluorescent light with a maximum sensitivity at 525 nm. The decrease in fluorescence intensity over time is then converted into GFR.
Proteinuria. Urine protein content was determined using the Bradford Assay. 3 µl of urine and 150 µl of 1x Bradford reagent were mixed, incubated at RT for 5 min and absorbance was measured at 595 nm. (5x Bradford reagent was prepared by dissolving 50 mg Brilliant Blue G-250 (Sigma, B-1131) in 24 ml ethanol and 50 ml 85% phosphoric acid, then adjusting the total volume to 100 ml with ultra-pure water). Urine creatinine content was determined using the Jaffe method. 10 µl of 1:10 diluted urine was mixed with 100 µl Creatinine reagent, incubated at RT for 10 min and absorbance was measured at 510 nm. (Creatinine reagent consisted of 10 mM picric acid and 250 mM NaOH, pH 13). Finally, the protein creatinine ratio was calculated for each sample.
Glomerular count. 100 µm Z-stack images of whole-mount E18.5 kidneys stained for nephrin (R&D AF3159) were analysed with the open source image processing software Fiji (lmageJ, version 2.0.0-rc69/1.52i, https://imagej.net/Fiji). In the TrackMate v3.8.0 plugin, the Downsample LoG detector was set to 80.0 pixel for the estimated blob diameter with a 16-pixel threshold and downsampling factor 2. The number of spots per frame were added to mice, the number of glomeruli per kidney was calculated. A 100 µm distance between frames was chosen to avoid double counting of identical glomeruli in consecutive images, given an average glomerular diameter of 80 µm.
Microarray analysis. Total RNA from male hypoxic, normoxic and caloric control group E18.5 kidneys was isolated using the RNeasy Mini Kit (Qiagen, 74104). Only high quality RNA (RIN>8, 260/280 ratio>2, 260/230 ratio>1.8) was used for further analysis. 100 ng total RNA samples were processed with the Ambion® WT Expression Kit (4411973, life technologies) kit. 5.5 µg of the cDNA was fragmented and labelled with GeneChip® WT Terminal Labeling kit (901525, Affymetrix). 2.3 µg biotinylated fragments were hybridized to Affymetrix Mouse Gene 1.0 ST arrays at 45° C. for 16 h, washed and stained according to the protocol described in Affymetrix GeneChip® Expression Analysis Manual (Fluidics protocol FS450_0007). The arrays were scanned with Affymetrix GeneChip® Scanner 3000 7G and raw data was extracted from the scanned images and analysed with the Affymetrix Power Tools software package. Hybridization quality was assessed using Affymetrix Expression Console software (version 1.1.2800.28061). Normalized expression signals were calculated from Affymetrix CEL files by the Robust Multi-array Average algorithm (RMA). Differential hybridized features were identified using the R Bioconductor package “limma” that implements linear models for microarray data. P values were adjusted for multiple testing with Benjamini and Hochberg’s method to control the false discovery rate (FDR). Probe sets showing at least 1.3-fold change and a FDR<0.05 were considered significant. Differential expression values between hypoxic, normoxic and caloric control group E18.5 kidneys were mapped with Heatmapper (http://www.heatmapper.ca) using average linkage and Euclidean distance measurement. For functional annotation, GO-term analysis was performed using the DAVID platform (https://david.ncifcrf.gov).
RT-qPCR. Total RNA was isolated using TRlzol® reagent (Invitrogen 15596026) according to the manufacturer’s protocol. RNA concentration and quality was determined with a Nanodrop 1000 spectrophotometer (ThermoFisher Scientific, Switzerland) and 1000 ng were transcribed into cDNA using PrimeScript RT Reagent Kit (Takara, RR037A). cDNA was diluted to 2 ng/µl and qPCR was performed with either TaqMan Gene Expression Assays (ThermoFisher) or FAM-labelled UPL probe (Roche) plus corresponding gene-specific primers and TaqMan Fast Universal PCR Master mix (Applied Biosystems, 4352042) on a 7500 Fast Real-Time PCR System (Applied Biosystems). Data analysis was performed with Microsoft Excel. The 2(-ΔCt) method was used to calculate the relative expression levels for RT-qPCR.
Identification of HIF binding sites. For the identification of putative HIF binding sites, the 20 kb genomic region overlapping with the Ahsg locus (10 kb up- and downstream of the start codon) of 15 different species (cat, chicken, chimp, cow, dog, ghost shark, horse, human, mouse, pig, rabbit, rat, sheep, xenopus, zebrafish) was analysed with the JASPAR database (http://jaspar.genereg.net). The relative profile score threshold was set to 90%. For enrichment analysis, putative sites of all species were clustered in 1kb windows. HREs with a relative score >0.9, >0.93 and >0.97 are shown. For the alignment of human HIF alpha sites identified by ChlP-seq of hypoxic MCF7 cells (cf. Schodel J, Oikonomopoulos S, Ragoussis J, Pugh CW et al. Blood 2011 Jun 9;117(23):e207-17.; Series GSE28352; https://www.ncbi.nlm.nih.gov/ geo/query/acc.cgi?acc=GSE28352) with active regulatory marks of the AHSG locus, the HIF-1-alpha and HIF-2-alpha data sets encompassing chr3: 180,000,000-190,000,000 (including the AHSG locus) were converted into BAM files using the web-based Galaxy platform (https://usegalaxy.org) and uploaded to the human assembly GRCh37/hg19 on the USCS genome browser (https://genome.ucsc.edu). To this alignment, the following data sets were added: layered chromatin marks often found near active regulatory elements of 7 cell lines (H3K27Ac and H3K4Me1, ENCODE) and open chromatin of hypoxic MCF7 cells (DNasel HS, ENCODE). For the mouse Ahsg locus, the potential HIF binding sites identified with JASPAR were aligned with data sets (DNasel HS, ENCODE/UW; H3K27Ac and H3K4Me1, ENCODE/LICR) derived from 8 weeks mouse liver, heart and kidney, showing the mean signal intensity (bar graphs, auto-scaled, log-transformed, smoothened (16 pixels)).
Molecular cloning. For luciferase assays, the 2.5 kb promoter fragment upstream of the mouse Ahsg ATG was amplified from genomic DNA (C57BL/6) using specific primers and PrimeSTAR® GXL DNA Polymerase (Takara, R050A). The 500 bp promoter fragments (wt and mutant) and the 500 bp fragment of intronic sequences (wt and mutant) were synthesized by IDTDNA (https://eu.idtdna.com/pages). The promoter fragments were inserted into the pGL3-basic-P2P-607 plasmid with Ncol and Sacl restriction enzymes (both NEB, R3193S and R3156S). Intronic fragments were inserted into the pGL3- basic vector or the pGL3-basic vector carrying the promoter fragments using BamHl and Sall restriction enzymes (both NEB, R3136S and R3138S). For in-situ hybridization, the cDNA of exons 2-5 of mouse Ahsg was obtained from IDTDNA and cloned into pBluescriptll KS— using Spel and EcoRl restriction enzymes (both NEB, R3133S and R3101S).
Luciferase assay. 24 h after transfection, cells were washed twice with PBS, lysed (250 mM KCI, 50 mM Tris/H3PO4 pH 7.8, 10% glycerol, 0.1% NP40) on ice for 20 min and centrifuged at 14000 rpm at 4° C. for 10 min. Of the supernatant 10 µl were used for each reaction. Injection of reaction solutions (Luciferase: 100 µl of 25 mM Tris/H3PO4 pH 7.8, 10 mM MgSO4, 2 mM ATP pH 7.5, 50 µM luciferin; Renilla: 100 µl of 50 mM Tris/HCI pH 7.6, 100 mM NaCl, 1 mM EDTA, 0.5 µM coelenterazine) and activity measurement was performed with a Fluoroskan Ascent FL (ThermoFisher). Each sample was measured in duplicates and luciferase activity was normalized by renilla activity.
Whole-mount in situ hybridization. E18.5 kidneys were fixed in 4 % PFA, dehydrated and stored in methanol at -20° C. In situ hybridization using a digoxigenin-labelled riboprobe was performed as described in Rudloff, S. & Kemler, R. Differential requirements for beta-catenin during mouse development. Development 139, 3711-3721 (2012). Probes were generated using the DIG RNA Labeling Mix (Roche, 11175025910) and T3 or T7 RNA polymerase (both Roche, 11031163001 or 10881767001). An alkaline phosphatase-conjugated antibody was used to detect the DIG-labelled probes (Roche, 11093274910).
TUNEL staining. Fragmented DNA in apoptotic cells was detected using the Promega DeadEnd Colorimetric TUNEL System (G7360) according to the manufacturer.
Histochemistry. For immunohistochemistry, PFA-fixed, paraffin-embedded tissue sections were rehydrated and endogenous peroxidase was blocked by incubating the slides in 1.5 % H2O2 solution (0.02 M citric acid, 0.06 M Na2HPO4) at RT for 15 min in the dark. Antigen retrieval was performed by boiling in Tris-EDTA buffer pH 9 for 20 min followed by slow cool down to RT. After blocking in 2 % BSA in PBS at RT for 1 h, the sections were incubated with primary antibodies in blocking solution o/n at 4° C. Following three washing steps in PBS, the sections were incubated with HRP-conjugated secondary antibodies (mouse or rabbit: Dako EnVision+ System from Agilent (K4001 or K4003), goat: SCBT, sc-2304) for 1 h at RT. After three washing steps in PBS, the signal was developed with DAB (Agilent, K3468). The sections were counterstained with Harris haematoxylin solution (Sigma, HHS16), dehydrated and mounted using Eukitt medium (Sigma, 03989). For Picrosirius red staining of collagen, dewaxed, rehydrated tissue sections were incubated in staining solution (0.5 g Direct Red 80 in saturated aqueous solution of picric acid (both Sigma, 365548 and P6744)) for 1 h at RT. After washing twice in acidified water (0.5% glacial acetic acid), the sections were dehydrated and mounted using Eukitt.
Immunofluorescent staining. Cryosections were fixed in 4 % PFA at RT for 10 min, washed twice in PBS and permeabilised by incubation in PBST (0.1% Triton X-100 in PBS) at RT for 10 min. After blocking in 10 % FCS, 0.5 % Tween-20 in PBS at RT for 1 h, the sections were incubated with primary antibodies in blocking solution o/n at 4° C. Following three washing steps in PBS, the sections were incubated with fluorescence-conjugated secondary antibodies in blocking solution in the dark for 1 h at RT. DNA was stained with DAPI 1:5000 in PBS. Sections were mounted in MOWIOL solution (2.4 g MOWIOL 4-88 reagent (Merck, 475904) in 6 g glycerol and 18 ml 0.13 M Tris pH 8.5). For whole mount immunofluorescence staining of E18.5 kidneys, the iDisco staining protocol (https://idisco.info/idisco-protocol/) with methanol pre-treatment was applied. An incubation time n=1 day and a solution volume of 1.6 ml was used for the relevant steps. The kidneys were mounted in 8-well glass chamber slides (ThermoFisher, 154534) and imaged immediately.
Fluorescent detection of calcium. Thick cryosections (30 µm) were incubated with 10 ng/ml ATTO 488 fluorescently labelled Fetuin A (in calcium-free PBS) in the dark at RT for 60 min, rinsed 3 times with PBS and mounted with MOWIOL solution. Nuclei were counterstained with DAPI.
lmaging. Fluorescence imaging was performed on a IMIC digital microscope (FEI, Type 4001) using the Polychrome V light source, an Orca-R2 camera controller from Hamamatsu (C10600) and Live Acquisition software (FEI, version 2.6.0.14). Image analysis was performed using Offline Analysis software (FEI). Bright field imaging was performed on a Nikon E600 microscope equipped with Nikon objectives (Plan Fluor ELWD 20x/0.45, Plan Apo 40x/1.0 Oil and 60x/1.40 Oil) using a Digital Sight DS-UE camera controller and DSRi1 camera (both Nikon). Image analysis was performed using Nikon software NIS Elements 4.0.
ELISA. Mouse Fetuin A levels, e.g. in serum or renal tissue, were determined using the mouse-specific Fetuin A/AHSG Quantikine ELISA Kit (R&D, MFTA00) according to the manufacturer bio-techne. Human Fetuin A levels, e.g. in serum or renal tissue, were determined using the human-specific Fetuin A/AHSG Quantikine ELISA Kit (R&D, DFTA00) according to the manufacturer bio-techne.
Cell culture. The normal rat kidney (NRK) cell line was cultured in DMEM (Gibco, 41965- 039) and 10% fetal bovine serum (FBS). The human kidney (HK-2) cell line was cultured in Keratinocyte-SFM medium (Gibco, 17005-075). For luciferase assays, NRK cells were transfected with luciferase reporter plasmids and pCMV-Renilla (10% of total transfected DNA, used for normalization) using jetPrime® reagent (Polyplus, 114-07), stimulated with 1 mM DMOG (Echelon Biosciences, F-0010) 6 h after and harvested 24 h after transfection. For hypoxia, cell culture was performed at 0.2 % oxygen for 48 h. Primary proximal tubular cells (pPTC) were isolated from 3-4 weeks old kidneys (cf. Terryn, S. et al. A primary culture of mouse proximal tubular cells, established on collagen-coated membranes. Am J Physiol Renal Physiol 293, F476-485 (2007)). Briefly, proximal tubular fragments were obtained by digesting cortical kidney tissue with collagenase and filtration through an 80 µm pore size membrane. pPTCs were cultured in DMEM/F12 (Gibco, 21041-025) supplemented with 15 mM HEPES, 0.55 mM NaPyruvate, 1% NEAA and renal epithelial cell growth medium (REGM) supplements (Lonza, CC-4127). Instead of FBS, serum from Ahsg KO mice was used. Upon confluency, pPTCs were split and replated once using Accutase solution (Sigma, A6964). For 24 hypoxia, cell culture was performed at 0.2 % oxygen for 48 h. 100 µg/ml Fetuin A (Sigma, F3385) or bovine serum albumin (BSA, Sigma, A3059) was added to the culture medium 48 h before the end of the experiment. Before treatment with 5 ng/ml rmTGF-β1 (R&D, 7666-MB) for 5 min, cells were starved for 24 h.
Western blot analysis. Total protein lysates were obtained using RIPA buffer (Sigma, R0278) supplemented with protease inhibitors (Roche, 11836153001). Proteins were separated by SDS-PAGE and blotted onto PVDF membranes (ThermoFisher, 88518). Upon blocking with 5 % milk in TBST, the membranes were incubated with primary antibodies at 4° C. o/n, incubation with HRP-conjugated secondary antibodies was performed at RT for 1 h. The signal was detected with ECL (GE Healthcare, RPN2106) or SuperSignal (ThermoFisher, 34076) depending on signal intensity. Densiometric analysis was performed with the open source image processing software Fiji (lmageJ, version 2.0.0-rc69/1.52i, https://imagej.net/Fiji).
Calculation of concentration for intraperitoneal injected bovine Fetuin A in the mouse. The reference blood volume of mice was 58.5 ml/kg (nc3rs.org.uk), 77-80 ml/kg (jax.org). Based on these values, 68.5 ml/kg was used for calculations. The calculated molecular weight of bovine Fetuin A (UniProtKB - P12763 (FETUA_BOVIN)) is 38.4 kDa. Thus, a concentration of 38 µM in the blood would be reached, if all injected Fetuin A was in the blood or if intravenous injection of Fetuin A was performed. Furthermore, Fetuin A undergoes posttranslational modifications. Here, especially glycosylation plays a predominant role, increasing the molecular weight to 51-67 kDa. Therefore, a molecular weight of 60 kDa was used in the calculation (where 1 Da = 1 g/mol). This results in a concentration of 24.3 µM in the blood of injected mice, if all injected Fetuin A was in the blood or if intravenous injection of Fetuin A was performed and based on the injected amount of 100 µg/g body weight:
However, intraperitoneal injections were performed, which results in lower concentrations in the blood, because Fetuin A has to be transported from the abdominal cavity into circulation. During this process, not all molecules will be absorbed, due to partial degradation in the cavity or pinocytosis and metabolization by mesothelial cells. In a study (Regoeczi et al (1989), Am J Physiol.; 256(4 Pt 1): E447-52), it was shown that intraperitoneal injection of albumin reached approximately 40 % of the dose in the blood after 2-3 hours compared to the intravenous injection of the same amount of albumin. Based on a 40 % uptake in mouse the resulting concentration after intraperitoneal injection is:
Therefore, if 100 mg/kg body weight of Fetuin A is injected intraperitoneal, the resulting concentration in blood would be about 9.7 µM. As described above, it was found that such a relatively low dose is sufficient to treat renal ischemic damages.
Calculation of concentration for intravenous injected human Fetuin A in the mouse. The reference blood volume of mice was 58.5 ml/kg (nc3rs.org.uk), 77-80 ml/kg (jax.org). Based on these values, 68.5 ml/kg was used for calculations. The calculated molecular weight of human Fetuin A (UniProtKB - P12763 (FETUA_BOVIN)) is 38.4 kDa. Furthermore, Fetuin A undergoes posttranslational modifications. Here, especially glycosylation plays a predominant role, increasing the molecular weight to 51-67 kDa. Therefore, a molecular weight of 60 kDa was used in the calculation. In the experiments for prophylactic treatment, the mice had an average body weight of 22 g. For a mouse with a body weight of 22 g the corresponding blood volume is about
With an injection of 900 µg of human Fetuin A this results in a concentration in blood of
Therefore, if 900 µg of human Fetuin A is injected intravenously in mice having an average body weight of 22 g, the resulting concentration in blood would be about 9.9 µM. As described above, it was found that such a relatively low dose is sufficient to prevent renal ischemic damages.
Calculation of concentration and dosing for human Fetuin A in humans. The reference blood volume for a human adult is 77 ml/kg (male) and 65 ml/kg (female), which is an average volume of 71 ml/kg. The molecular weight of human Fetuin A (UniProtKB - P02765 (FETUA_HUMAN) is generally comparable to bovine Fetuin A, i.e. also about 60 kDa (with glycosylation). For administration of 10 mg/kg (iv), 25 mg/kg (iv), 50 mg/kg (iv) of Fetuin A to a human adult the resulting concentration in human blood would be:
Similarly, it can be calculated which dose corresponds to the above mentioned concentration of 9.7 µM:
Similarly, it can be calculated which dose corresponds to the above mentioned concentration of 9.9 µM:
Therefore, the calculated equivalent to 100 µg/g body weight of Fetuin A being injected intraperitoneal to a mouse, is about 41.3 mg/kg when injected intravenously into an adult human and the calculated equivalent to 900 µg of Fetuin A being injected intravenously to a mouse with a body weight of 22 g is about 42.2 mg/kg when injected intravenously into an adult human.
Data analysis. Statistical analysis and graphs were performed with Prism 7 (https://www.graphpad.com). Two groups were compared by t-tests, multiple groups by one-way ANOVA (Tukey’s multiple comparisons test, unless specified otherwise). ****, P<0.0001; ***, P<0.001; **, P<0.01; *, P<0.05; ns, not significant; Error bars, standard deviation (SD); Whiskers, min to max.
| Number | Date | Country | Kind |
|---|---|---|---|
| 20162490.5 | Mar 2020 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2021/056253 | 3/11/2021 | WO |
